Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety

Masahiro Tsuji1,2, Mariko Sawada3, Shinichi Watabe3, Hiroyuki Sano4, Masayo Kanai5, Emi Tanaka6, Satoshi Ohnishi6, Yoshiaki Sato7, Hisanori Sobajima3, Takashi Hamazaki6, Rintaro Mori6, Akira Oka9, Hiroyuki Ichiba10, Masahiro Hayakawa10, Satoshi Kusuda11, Masanori Tamura5, Makoto Nabetani4* & Haruo Shintaku6*

Neonatal hypoxic-ischaemic encephalopathy (HIE) is a serious condition; many survivors develop neurological impairments, including cerebral palsy and intellectual disability. Preclinical studies show that the systemic administration of umbilical cord blood cells (UCBCs) is beneficial for neonatal HIE. We conducted a single-arm clinical study to examine the feasibility and safety of intravenous infusion of autologous UCBCs for newborns with HIE. When a neonate was born with severe asphyxia, the UCB was collected, volume-reduced, and divided into three doses. The processed UCB was infused at 12–24, 36–48, and 60–72 hours after the birth. The designed enrolment was six newborns. All six newborns received UCBC therapy strictly adhering to the study protocol together with therapeutic hypothermia. The physiological parameters and peripheral blood parameters did not change much between pre- and postinfusion. There were no serious adverse events that might be related to cell therapy. At 30 days of age, the six infants survived without circulatory or respiratory support. At 18 months of age, neurofunctional development was normal without any impairment in four infants and delayed with cerebral palsy in two infants. This pilot study shows that autologous UCBC therapy is feasible and safe.

Acute brain dysfunction may occur unexpectedly during and immediately after birth. Brain dysfunction noted immediately after birth, from any cause, is collectively termed neonatal encephalopathy1. The signs and symptoms of neonatal encephalopathy include altered levels of consciousness, weak muscle tone, impaired feeding, respiratory distress, and seizures. In many infants with neonatal encephalopathy, the pivotal pathophysiology is an insufficient supply of blood flow and oxygen to the brain in the ante-, intra-, or very immediate postpartum period. In these cases, neonatal encephalopathy is named hypoxic-ischaemic encephalopathy (HIE)2. Mild hypothermia is the only therapy proven effective for term newborns with HIE3,4. Even if infants with HIE receive therapeutic hypothermia, 40–44% die or survive with severe neurological impairments, including cerebral palsy and intellectual disability3,4. The therapeutic time window is within 6 hours after birth for hypothermia to be effective3,5,6. Hence, it is an urgent task to develop a novel therapy for HIE, especially a therapy with a long therapeutic time window7.

Cell-based therapy has attracted much attention because of not only its regenerative property but also its long therapeutic time window8. Preclinical studies with animal models with neonatal encephalopathy show that cell therapies initiated hours or days after the injury are beneficial. Although a variety of cell therapies have been...
were 0.3–9.7 thus far\(^1\)\(^-\)\(^2\)\(^5\)–\(^2\)\(^5\). Most of these preclinical studies used the mononuclear cell (MNC) fraction of human UCBCs, and tumourigenicity, low immunogenicity, and easy preparation are critical.

Several preclinical studies on the systemic administration of UCBCs for neonatal HIE have been published thus far\(^1\)\(^1\)\(^-\)\(^2\)\(^5\). Most of these preclinical studies used the mononuclear cell (MNC) fraction of human UCBCs, and the cells were transfused either intraperitoneally or intravenously. Almost all studies demonstrated the beneficial effects of UCBC treatment, although publication bias cannot be ruled out. Our research group, named the Neonatal Encephalopathy Consortium Japan, conducted preclinical studies before translating UCBC therapy to the clinic. We demonstrated that the intravenous infusion of human CD34\(^+\) cells (haematopoietic stem/endothelial progenitor cells) at 48 hours after brain injury partially ameliorated the damage in mouse models of neonatal stroke\(^2\)\(^6\) and neonatal HIE\(^2\)\(^7\). Additionally, we have demonstrated that intraperitoneal infusion of the MNC fraction of human UCBCs at 6 hours after brain injury partially ameliorates the damage in a rat model of neonatal HIE\(^9\).

Regarding the intravenous infusion of autologous UCBCs for newborns with neonatal HIE, two clinical studies (NIH ClinicalTrials.gov website; NCT00593242, NCT01506258) apart from our study have been completed, and only one of these studies, which was conducted in the U.S., has been published\(^1\)\(^8\).

In this article, we present the protocol and results of our pilot study on the feasibility and safety of the intravenous administration of autologous UCBCs for newborns with HIE.

**Results**

**Study outline.** This clinical study strictly adhered to the study protocol as well as the standard operating procedure (SOP) for UCB processing, and there was no deviation from the protocol. The schema of this study is shown in Fig. 1. The review board of this multicentre clinical study approved proceeding to the third case after the interim assessment of the first two cases and then approved the adherence and safety and feasibility of this protocol after the final assessment of the six cases.

This clinical study started in 2015. The first case enrolment was in May 2015, and the final case enrolment occurred in September 2017. The reason why it took more than two years to enrol six cases was that we recruited only infants born via caesarean section in hospitals of our study group in order to secure the quality of UCB collection. As the majority of infants in Japan are born in private obstetrics clinics or small community hospitals, many HIE cases occur there and are then transferred to general hospitals with neonatal intensive care units (NICUs). All parents of eligible newborns, excluding one newborn, consented to their child’s enrolment in the study. We could not enrol that eligible case because the mother and grandmother had an intellectual disability and we could not get in contact with the father.

**Baseline characteristics of the cases.** The characteristics of the six newborns are shown in Table 1. Four boys and two girls were enrolled. Three of these newborns were recruited at Kurashiki Central Hospital, and the remaining three were recruited at Yodogawa Christian Hospital, Saitama Medical Center, and Osaka City University Hospital. The causes of asphyxia were of foetal origin in four cases and maternal origin in two cases. Foetal causes included premature abruption of the placenta, prolapse of the cord, nonreassuring foetal distress due to an anomaly of rotation or difficulty of head ejection during birth. Maternal causes included cardiopulmonary arrest due probably to amniotic fluid embolism and loss of consciousness due to subarachnoid haemorrhage. The causes of asphyxia were of foetal origin in four cases and maternal origin in two cases. Foetal causes included premature abruption of the placenta, prolapse of the cord, nonreassuring foetal distress due to an anomaly of rotation or difficulty of head ejection during birth. Maternal causes included cardiopulmonary arrest due probably to amniotic fluid embolism and loss of consciousness due to subarachnoid haemorrhage. The median base deficit of the UCB or first blood sample from the newborn was 7.16 (range, 6.96 to 7.23). The median base deficit of the UCB or first blood sample from the newborn was 7.16 (range, 6.96 to 7.23). The median base deficit of the UCB or first blood sample from the newborn was 7.16 (range, 6.96 to 7.23). The median base deficit of the UCB or first blood sample from the newborn was 7.16 (range, 6.96 to 7.23).

**Cord blood data.** In all cases, we attempted to collect UCB, and we succeeded in doing so. The volumes of collected UCB were 40–113 mL (Table 2). Total nucleated cell numbers after processing were 1.4–10.9 × 10\(^8\), which were equally divided into three doses and administered intravenously. The CD34\(^+\) cell doses administered were 0.3–9.7 × 10\(^8\). The retrieval rates of CD34\(^+\) cells after processing were more than 90% in three cases but less.

---

**Figure 1.** Schema of the clinical study: timing of the cell infusions and clinical examinations. DQ: developmental quotients, UCBCs: umbilical cord blood cells.
than 50% in two cases. In Case no. 1, the test sample of the processed cell solution was taken from the upper part of the solution after maintaining it in a syringe for a certain period of time.

**Cell transfusions and possible adverse events.** The first infusion of processed UCB was performed between 16 hours and 22 hours after birth. There were no acute adverse events during the infusion or within the first few hours after the infusion. Table 3 presents the values in blood analyses and the physiological parameters at preinfusion (immediately before the first infusion), postfirst infusion (2 hours after the first infusion), and postthird infusion (24 hours after the third infusion). Figure 2 demonstrates the temporal changes in the major values and parameters. With respect to changes between preinfusion and postfirst infusion, there was no constant significant change in those values or parameters. Although C-reactive protein (CRP) levels were uniformly elevated after the first cell infusion, the elevation was minimal, namely, 0.3 mg/dL at maximum, and this temporal change was not statistically significant. The base deficit was exacerbated in four cases (2.9 mol/L increase at worst) but ameliorated in two cases. Systolic blood pressure was uniformly elevated after the first infusion; the median elevation was 10 mmHg, ranging from 2–21 mmHg. This temporal change, however, did not reach statistical significance. Neither the CD34 \(^+\) cell counts nor the leukocyte counts in peripheral blood were elevated. With respect to changes between postfirst infusion and postthird infusion, there were significant changes in three of those values and parameters shown in Table 3; the base deficit decreased (improved), \(\text{HCO}_3\) increased, and the body temperature rose. The heart rate uniformly rose, but the temporal change did not reach statistical significance. None of these changes was considered to be caused by UCBC infusions but, rather, a result of the anticipated clinical course with medical care and cessation of therapeutic hypothermia.

**Table 1.** Baseline clinical characteristics of six cases. *Venous blood analysis, in which sample was obtained at 26 minutes after birth. CPA: cardiopulmonary arrest, LC: loss of consciousness.

**Table 2.** Cord blood data. The data of three types of samples; 1) cord blood collected from a newborn, 2) the total dose of processed cord blood, and 3) each dose to be infused after dividing into three equal doses. TNCs: total nucleated cells. Notably, the data in Case no. 1 may not be accurate, as the test sample of the processed cell solution was taken from the upper part of the solution after maintaining it in a syringe for a certain period of time.
Three infusions were successfully completed in each of six infants, and no adverse events were noted (Table 4).

| Case no. 1 | Case no. 2 | Case no. 3 | Case no. 4 | Case no. 5 | Case no. 6 | temporal change |
|------------|------------|------------|------------|------------|------------|----------------|
| pre        | post 1st   | post 3rd   | pre        | post 1st   | post 3rd   | pre           | post 1st | post 3rd | pre           | post 1st | post 3rd |
| **Peripheral blood** |           |            |           |            |            |                |            |            |                |            |          |
| WBCs (/μL)  | 11,700     | 10,800     | 7,600     | 24,600     | 22,300     | 15,000        | 24,700     | 22,500     | 13,100        | 18,600    | 21,600   |
| CD34+ cells (/μL) | 11.7 | 10.8 | 3.04 | 14.7 | 14.7 | 7.38 | 8.26 | 5.48 | 7.65 | 32.3 | 30.7 | 11.8 |
| Ht (%)      | 51.5 | 49.2 | 67.1 | 61.8 | 46.9 | 54.6 | 51.3 | 40.4 | 48.0 | 47.7 | 39.7 | 37.6 | 39.1 | 34.6 | 40.5 | 42.7 | 35.5 |
| PLT (x10^3/μL) | 171 | 185 | 115 | 266 | 260 | 191 | 233 | 229 | 214 | 220 | 218 | 245 | 187 | 208 | 183 | 207 | 240 |
| CRP (mg/dL) | 0.39 | 0.41 | 0.41 | 0.55 | 0.64 | 0.20 | 1.0 | 1.1 | 0.5 | 0.29 | 0.49 | 0.06 | 0.08 | 0.02 | 0.05 | 0.32 | 0.18 |
| LDH (U/L)   | 1,053 | 1,010 | 694 | 782 | 671 | 673 | 1.004 | 865 | 497 | 573 | 677 | 587 | 691 | 626 | 395 | 398 | 406 |
| CK (IU/L)   | 2,059 | 2,132 | 441 | 1,139 | 1,080 | 1,257 | 402 | 298 | 84 | 1,275 | 1,731 | 143 | 247 | 247 | 103 | 221 | 221 |
| **Blood gas (artery)** |           |            |           |           |            |                |            |            |                |            |          |
| pH          | 7.439 | 7.407 | 7.331 | 7.338 | 7.421 | 7.294 | 7.340 | 7.302 | 7.370 | 7.352 | 7.372 | 7.400 | 7.419 | 7.334 | 7.307 | 7.450 |
| PO2 (mmHg)  | 175 | 185 | 81.2 | 121 | 125 | 92.6 | 93.1 | 104 | 80.6 | 117 | 106 | 95.9 | 70.6 | 77.3 | 113 | 132 | 103 |
| PCO2 (mmHg) | 29 | 26.4 | 49.9 | 35.8 | 36.2 | 42.1 | 46.2 | 38.2 | 51 | 41.2 | 36.3 | 46.5 | 38.9 | 36.3 | 34.9 | 43.4 | 45.7 |
| HCO3− (mol/L) | 19.6 | 16.6 | 17.6 | 18.9 | 26.8 | 21.7 | 20 | 24.5 | 23.8 | 22.1 | 25.8 | 22.6 | 22.5 | 22.6 | 22.1 | 21.2 | 29.2 |
| Base deficit (mol/L) | 3.9 | 6.8 | 0.1 | 7.4 | 5.6 | 2.5 | 3.8 | 4.8 | −1.1 | 1.5 | 2.5 | 0 | 2.5 | 2.0 | −1.7 | 2.5 | 3.2 | −5.5 |
| Body temperature (°C) | 33.5 | 33.5 | 36.2 | 33.5 | 36.8 | 34.0 | 34.0 | 36.8 | 33.6 | 33.5 | 37.2 | 33.5 | 33.5 | 36.8 | 33.4 | 33.6 | 37.2 |
| Heart rate (/min) | 91 | 95 | 101 | 110 | 120 | 145 | 110 | 120 | 149 | 106 | 100 | 124 | 92 | 72 | 119 | 95 | 92 |
| Diastolic blood pressure (mmHg) | 38 | 45 | 37 | 40 | 38 | 36 | 39 | 36 | 32 | 37 | 53 | 35 | 31 | 35 | 36 | 35 | 41 |
| Systolic blood pressure (mmHg) | 52 | 64 | 52 | 49 | 51 | 61 | 54 | 60 | 51 | 53 | 74 | 61 | 48 | 61 | 61 | 33 | 60 |
| Respirator mode | SIMV | SIMV | SIMV | SIMV | SIMV | HFO | HFO | HFO | SIMV | SIMV | SIMV | SIMV | SIMV | SIMV | SIMV | SIMV | SIMV |
| FiO2 (%) | 30 | 30 | 23 | 21 | 21 | 21 | 35 | 25 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Rate (/min) | 25 | 25 | 30 | 20 | 25 | 20 | 50 | 50 | 20 | 40 | 40 | 25 | 18 | 12 | 12 | 12 | 12 |
| MAP (cmH2O) | 6 | 6 | 6 | 5.5 | 5.5 | 6 | 12 | 12 | 11 | 6 | 6 | 6.3 | 6.2 | 6.2 | 6.1 | 6.1 |
| PEEP (cmH2O) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Thompson score | 15 | 12 | 12 | 15 | 9 | 9 | 12 | 12 | 15 | 15 | 9 | 9 | n.s. | n.s. | n.s. | n.s. | n.s. |

Table 3. Changes in blood and physiological parameters between pre- and postfirst infusion and postthird infusion. pre: immediately before the first cell infusion, post 1st: at 2 hours after the first cell infusion, post 3rd: at 24 hours after the third cell infusion. SIMV: synchronized intermittent mandatory ventilation, HFO: high frequency oscillation, MAP: mean airway pressure, PEEP: positive end expiratory pressure, SV: stroke volume, n.s.: not significant, *significant change between preinfusion and postfirst infusion or postfirst infusion and postthird infusion. **P value < 0.05, ***P value < 0.01.

Figure 2. Temporal changes in leukocytes (WBCs) and CD34+ cells in peripheral blood samples, heart rate, and systolic blood pressure, immediately before the first cell infusion, at 2 hours after the first cell infusion, and at 24 hours after the third infusion.
support, or death at 30 days of age. Therefore, the primary outcome was zero out of six cases. Five infants were orally fed, and one infant was tube fed at 30 days of age. Other complications included seizures in two cases and hypotension, coagulopathy, weak cardiac muscle contraction, and hyperglycaemia in one case, all of which responded to treatments. It is unlikely that those complications were the result of UCBC infusions.

**Neurological outcomes.** The secondary outcome measures were neuroimaging at 12–18 months of age and neurodevelopmental level at 18 months of age. Brain MRI showed abnormalities in the bilateral basal ganglia and thalamus in two infants and no abnormalities in four infants (Table 4). Brain MRI at 10–13 days after birth showed the same abnormalities in the bilateral basal ganglia and thalamus in two infants, trivial intraventricular and subdural haemorrhage in one infant, and no abnormality in the remaining three infants (Table 4).

All six infants were examined by the Kyoto Scale of Psychological Development at 18 months of age, which is the most widely used test for neurological development in Japan, and no infant was examined via Bayley III. Four infants were in good physical condition without any sequelae at 18 months of age. The developmental quotients (DQs) for these infants were higher than 85 (range, 88–110). Two other infants had neurofunctional impairments and developmental delays. Case no. 2 had spastic cerebral palsy and profound developmental delay, that is, he could not control his head or pursue objects. This infant could not be fed orally and was therefore fed via a catheter set by percutaneous endoscopic gastrostomy. He exhibited West syndrome, and his respiratory condition was not stable, necessitating the use of oxygen and respiratory support with nasal bilevel positive airway pressure during night sleep. The general condition of Case no. 3 was good, although this infant had mild spastic cerebral palsy. She could sit and stand up alone but could not walk yet. Her DQ was 55.

### Table 4. Outcomes and possible adverse events

DQ scores were evaluated by the Kyoto Scale of Psychological Development. bil.: bilateral, IVH: intraventricular haemorrhage, CP: cerebral palsy.

| Case no. | 24 h after the third infusion | (91–95 hours of age) | 10–13 days of age | 30 days of age | 18 months of age |
|---------|-------------------------------|---------------------|-----------------|----------------|----------------|
|         | Respiratory support          | Use of oxygen       | Use of vasopressor | Head MRI       | Use of oxygen       | Use of vasopressor | Feeding | Seizures | Anti-convulsant | CP | MRI/CT | DQ score | Postural-Motor | Cognitive-Adaptive | Language-Social |
| Case no. 1 | +                             | +                   | no               | normal         | no               | no               | oral    | none     | none           | – | not examined | 88        | 102              | 85                | 89                |
| Case no. 2 | +                             | –                   | no               | T2 high intensity in bil. basal ganglia & thalamus | no               | no               | tube feeding | none     | none           | + | bil. lesions in basal ganglia & thalamus | 55       | 47               | 58                | 48                |
| Case no. 3 | +                             | –                   | no               | mild T1 high intensity in bil. basal ganglia & thalamus | no               | no               | oral    | none     | none           | – | normal        | 110       | 109              | 107               | 117               |
| Case no. 4 | +                             | –                   | no               | normal         | no               | no               | oral    | none     | none           | – | normal        | 109       | 95               | 109               | 116               |
| Case no. 5 | +                             | –                   | no               | normal         | no               | no               | oral    | none     | none           | – | normal        | 108       | 131              | 96                | 122               |
| Case no. 6 | –                             | –                   | no               | normal         | no               | no               | oral    | none     | none           | – | normal        | 109       | 109              | 109               | 109               |
Discussion

The aim of this clinical study was to examine the feasibility and safety of autologous UCBC infusion in newborns with HIE. Our treatment protocol prioritized the feasibility foremost. The cell doses administered were not adjusted and inherently determined by the volumes of collected UCB and the numbers of cells in it, as autologous UCB was used. The timings of cell infusion were extrapolated from animal studies considering the safety of noncryopreserved UCB. Some of the data of this clinical study have already been published, i.e., the brief data on early time points from five of the six cases. In this article, we have presented more detailed data up to 18 months of age from all six cases.

We assumed that the following two issues might be crucial in this study: (1) collecting a sufficient volume of UCB in clinical emergencies, i.e., birth of critically ill newborns with asphyxia, and (2) the sterility of the UCB. In all cases, we tried to collect UCB, and we successfully collected an adequate volume of it with no bacterial contamination. There were no problems in volume-reducing processing with the automated centrifugation machine or preserving the processed UCB until use. The retrieval rates of CD34+ cells after processing were less than 50% in the first two cases. The actual retrieval rate in Case no. 1 was not that low, as the test sample of the processed UCB was drawn out of the upper part of the UCB kept in a syringe for a certain period, i.e., we assumed that the upper part of the UCB might have become like a supernatant with fewer cells. We shared this information among our study group members. Subsequently, test samples were drawn after mixing the UCB in a syringe. The low retrieval rate of CD34+ cells in Case no. 2 was probably due to the fact that the UCB volume before processing was the lowest possible volume for automated processing, which might have caused many CD34+ cells to be removed from the final UCB product together with red blood cells (RBCs). A study showed that small volumes of bone marrow resulted in lower leukocyte recovery by the automated Sepax®. In the other four cases, the retrieval rates were sufficiently high, 77% in one case and more than 90% in the other three cases.

The main safety issue in this study was whether the physiological condition, especially circulatory and respiratory conditions, in severely ill infants would be stable during and after cell infusions. All six infants were sick in the perinatal period and received 72 hours of whole-body cooling initiated by 4 hours after birth; therefore, these infants were vulnerable to factors that might influence cardiovascular and respiratory status. We closely monitored the cardiovascular and respiratory status during the first several days of cell therapy. We did not find changes that might be caused by cell infusions. Additionally, we repeatedly analysed peripheral blood during the first several days of cell therapy. Even though the infants received concentrated UBC, the blood cell counts were not altered during the cell therapy period. CD34+ cell counts did not increase following UCB infusion, which was not unexpected as physiologically CD34+ cell counts rapidly decrease over the first few days of life. Returning 0.3–9.7 × 10^6 CD34+ cells did not prevent a decrease in the cell concentration in the peripheral blood.

As the cells were autologous UCBCs with minimal processing, the tumourigenicity of the infused cells was not an issue. Therefore, the primary outcome measure of this study was set as a combined rate of circulatory stability, respiratory stability, and death at 30 days of age. All six participants of this study survived up to the end of the observation period, i.e., 18 months of age. There was not a single case that required ventilatory support, such as the use of vasopressors, or respiratory support, such as the use of oxygen at 30 days of age. However, one infant later required the use of oxygen and respiratory support during night sleep.

Recently, the Baby Cooling Registry of Japan Collaboration Team reported data collected from 485 HIE infants who received therapeutic hypothermia from 2012 to 2014. The basic characteristics of each of the study participants are similar, although the severity of HIE was slightly milder in the present study (Table 5). The rates of adverse events in the present study were similar to or somewhat milder than those in the report. The report did not include neurological outcomes, such as the mean DQ and rate of cerebral palsy.

To the best of our knowledge, three clinical studies, including ours, on the intravenous infusion of autologous UCBC therapy for neonatal encephalopathy have been completed according to the NIH website, ClinicalTrials.gov: ClinicalTrials.gov Identifier NCT02256618 (ours), NCT (Singapore) and NCT00593242 (USA). Only one (NCT00593242) of these studies has been published. This study was a single arm study with 23 infants treated with the intravenous infusion of volume-reduced noncryopreserved UCBCs. No severe adverse events that might be associated with the cell infusions were observed. The outcome was similar to ours. The feasibility and safety of the intravenous infusion of cryopreserved autologous UCB have been reported in a series of studies in children with cerebral palsy.

The present study was a small single arm study. Therefore, it is not possible to evaluate the beneficial effect of UCBC therapy. Four out of six infants who received therapy survived without any noticeable sequelae and with a DQ higher than 85, while the remaining two infants developed cerebral palsy, and one of the two infants had a profound intellectual disability with West syndrome. This infant with the most severe sequelae could have been worse, as his Apgar score was 1 at 10 minutes after birth and the Sarnat stage was grade III.

This treatment protocol may not be the most effective one. Further preclinical studies are needed to optimize the treatment and protocol. To the best of our knowledge, no preclinical study has thoroughly examined the optimal timing of UCBC infusion in models with neonatal brain injuries. In the literature, almost all preclinical studies on neonatal brain injuries examined the effects of UCBC administration at only one timepoint. Many such studies reported beneficial effects of UCBC administration at 24 or 48 hours after brain injury. Preclinical studies on other types of cells and/or in other models have demonstrated that early administration, i.e., a few hours after brain injury is not as beneficial as later administration, such as 24–72 hours after brain injury. Similarly, much later administration, such as later than 10 days after brain injury, is not beneficial either. Moreover, there is no preclinical evidence to guide the combined hypothermia plus UCBC treatment; all preclinical studies with UCBCs examined the effects of cell treatment alone. Preclinical studies on mesenchymal stem cells (MSCs) reported contradicting interactions with hypothermia. Herz et al. reported detrimental interactions between hypothermia and delayed murine bone marrow-derived MSC therapy, while Park, Ahn, et al. reported benefits when human UCB-derived MSCs were administered pre- and post-hypothermia.
The feasibility and safety of the intravenous transfusion of autologous UCBCs for newborns with HIE along with therapeutic hypothermia was shown in this pilot study. The next step is to examine the safety and efficacy of this therapy in a randomized control study with a larger number of patients.

Methods
We designed a protocol for our clinical study based on our preclinical studies and taking the feasibility of the cell therapy into consideration. Our protocol was mostly adjusted to that of the published clinical study in the U.S.26, as we may be able to collaborate in conducting a large-scale international phase 3 trial in the future. This clinical study was carried out in accordance with relevant guidelines and regulations, including the Declaration of Helsinki and the Act on Securement of Safety of Regenerative Medicine, Japan. Our protocol and other related documents, including an informed consent form for parents, were approved by the Ethics Committees of Osaka City University Graduate School of Medicine and institutional review boards (IRBs) of six other participating institutes. Additionally, our protocol and related documents were approved by the Certified Committee for Regenerative Medicine set by the Ministry of Health, Labor and Welfare of Japan. Our study was registered at the NIH ClinicalTrials.gov website (ClinicalTrials.gov Identifier: NCT02256618; date of registration, 3rd of October, 2014) and the UMIN (University Hospital Medical Information Network Japan) website.

This study was a multicentre pilot study to evaluate the feasibility and safety of the intravenous infusion of autologous UCBCs in term newborns with HIE. The study was an open-label, single-group assignment, and the number of planned enrolments was six.

The participants in this study were recruited from seven NICUs in Japan: Kurashiki Central Hospital, Yodogawa Christian Hospital, Saitama Medical Center, Osaka City University Hospital, Osaka City General Hospital, Nagoya University Hospital, and The University of Tokyo Hospital. All pregnant women admitted to the hospitals for delivery received explanations of a possible case of UCB collection for this clinical study in advance, and verbal consent was obtained. If their babies were born by caesarean section due to foetal distress or other medical problems and if the infants had severe asphyxia, then their UCB were collected with special care to avoid contamination. Immediately after the placenta was delivered, the umbilical cord was disinfected with iodine solution. A needle connected to a tube and to a collection bag was inserted into the umbilical vain so that the UCB spontaneously drained into the collection bag containing an anticoagulant, namely, citrate-phosphate-dextrose-adenine (CPDA), inside. Then, the UCB was stored at 4 °C. If a neonate presented with signs and symptoms of moderate to severe encephalopathy and met the criteria for therapeutic hypothermia, then whole-body cooling (33.5 °C) was initiated by 4 hours after the birth, and the neonate was considered for enrolment into this clinical study. The inclusion and exclusion criteria for this study were consistent with those

| Apgar score | Present study | Reference* |
|-------------|---------------|-------------|
| 1 min       | 2 (0–5)       | 1 [1–3]     |
| 5 min       | 4 (0–7)       | 4 [2–5]     |
| 10 min      | 6 (1–9)       | 5 [3–7]     |

| Cord or first blood gas | Present study | Reference* |
|-------------------------|---------------|-------------|
| pH                      | 7.16 (6.96–7.23) | 6.94 ± 0.21 |
| base deficit (mmol/L)   | 8.4 (5.1–20.0)   | 14.6 ± 10.5 |

| Sarnat staging | Present study | Reference* |
|----------------|---------------|-------------|
| stage I        | 0             | 11.7        |
| stage II       | 83            | 61.1        |
| stage III      | 17            | 27.2        |
| Hypotension    | 17            | 34.8        |
| Seizures       | 33            | 24.7        |
| Coagulation disorders | 17      | 13.2        |
| Arrhythmia     | 0             | 1.4         |
| Weak cardiac muscle contraction | 17     | n/a         |
| Hyperglycemia  | 17            | n/a         |
| Hypoglycemia   | 0             | 1           |
| Septicemia     | 0             | 0.8         |
| Subcutaneous fat necrosis | 0       | 0.4         |
| Dependence on tube feeding | 17     | 18.6        |
| Dependence on respiratory support | 0      | 9.7         |
| Death before discharge | 0         | 2.7         |

Table 5. Comparison of the present study and a recent cohort study. Reference; Tsuda et al., Sci Rep 2017. The Apgar scores are presented as the median and range in the present study and as the median and interquartile range in the reference study. The data from blood examinations are presented as the median and range in the present study and as the mean ± standard deviation in the reference study. All other data are presented as the ratio (%) of cases among study participants. n/a: data not available.
than 90% at up to 96 hours after cell processing and storage at 4 °C of the samples. Processed UCB was divided into three doses and intravenously administered at 12–24, 36–48, and 60–72 hours after the birth (Fig. 1). Before cell infusion, hydrocortisone (1 mg/kg body weight) was intravenously administered to reduce the possible risk of allergic reactions. As CPDA and HES were added to UCB, the risk of allergic reaction was not completely negligible.

The inclusion criteria were as follows:

1. Known major congenital anomalies, such as chromosomal anomalies and heart diseases
2. Major intracranial haemorrhage identified by brain ultrasonography or computed tomography
3. Severe growth restriction, with a birthweight of less than 1800 g
4. Severe infectious diseases, such as sepsis
5. Hyperkalaemia
6. Infants born at hospitals or clinics other than the study sites
7. Vaginal delivery
8. Volume of collected cord blood < 40 mL
9. Infants judged critically ill and unlikely to benefit from neonatal intensive care by the attending neonatologist

Soon after a newborn was confirmed to meet the criteria by the initial assessment, the physicians explained the clinical study to the parents. When the parents agreed to participate in the study, written parental consent was obtained twice: after the first explanation of the study, which was a few hours after birth, and before the first UCBC infusion, which was approximately 20 hours after birth.

RBCs in the UCB were removed, and the volume was reduced to 20 mL by centrifugation using an automated machine, Sepax® (Biosafe, Inc., Switzerland). UCB and hydroxyl ethyl starch (HES) (NIPRO Co., Ltd., Osaka, Japan) to remove RBCs were introduced into a rotating syringe. After centrifugation, the volume-reduced UCB was introduced into a set of three collection bags. All the processes were automatically managed by the manufacturer’s software and performed in a closed disposable kit provided by the manufacturers (Biosafe, Inc., and TERUMO Co., Ltd., Tokyo, Japan). The minimum amount of collected UCB for the inclusion criteria of this trial was 40 mL, as automated UCB processing may not be reliable if the processing volume is less than 40 mL. Processed UCB contains all types of nucleated cells, including a variety of stem cells, e.g., CD34+ haematopoietic stem/endothelial progenitor cells. Of note, the number of RBCs was significantly reduced but not completely eliminated from the final UCB solution to be infused. The processed UCB was stored at 4 °C until use. The cell dose was not adjusted in each case. Previously, we evaluated the quality of the processed UCB using UCB collected from volunteers and confirmed the sterility, low haemolysis, and high cell viability, e.g., the viability of CD34+ cells was more than 90% at up to 96 hours after cell processing and storage at 4 °C of the samples. Processed UCB was divided into three doses and intravenously administered at 12–24, 36–48, and 60–72 hours after the birth (Fig. 1). Before cell infusion, hydrocortisone (1 mg/kg body weight) was intravenously administered to reduce the possible risk of allergic reactions. As CPDA and HES were added to UCB, the risk of allergic reaction was not completely negligible even though the UCB was autologous. Each cell infusion was 6 mL in volume and 1 hour in duration using an infusion pump. No vehicle was used for delivery of the processed UCB. During the infusion, the processed UCB in a syringe was sometimes stirred by turning and rotating the syringe to avoid sedimentation of cells in the UCB. The condition of the infant, especially their circulatory and respiratory status, was closely monitored during and after the cell infusions. We set the primary outcome measure as the rate of adverse events, namely, the combined rate of three adverse events: death, continuous need of respiratory support, and continuous use of vasopressors at 30 days of age. The secondary outcome measure was efficacy, namely, neuroimaging at 12–18 months of age and neurodevelopmental level evaluated with the Bayley III or Kyoto Scale of Psychological Development at 18 months of age.

Statistical analysis was performed for the values in blood analyses and physiological parameters shown in Table 3. Temporal changes in each value or parameter among three time points, i.e., immediately before the first UCBC infusion, 2 hours after the first UCBC infusion, and 24 hours after the third UCBC infusion were analysed by Kruskal-Wallis test followed by Dunn’s post hoc test. The Thompson score was analysed by the Mann-Whitney U-test, as the score was evaluated at two time points, i.e., immediately before the first infusion and 24 hours after the third infusion. A P value < 0.05 was considered statistically significant.

Data availability
The datasets generated and analyzed during the current study are available from the corresponding authors on reasonable request.
References

1. Dammann, O., Ferriero, D. & Gressens, P. Neonatal encephalopathy or hypoxic-ischemic encephalopathy? Appropriate terminology matters. *Pediatr. Res.* **70**, 1–2 (2011).

2. Volpe, J. J. Neonatal encephalopathy: An inadequate term for hypoxic-ischemic encephalopathy. *Ann. Neurol.* **72**, 156–166 (2012).

3. Shankaran, S. et al. National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. *N. Engl. J. Med.* **355**, 1574–1584 (2006).

4. Gluckman, P. D. et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet* **365**, 663–670 (2005).

5. Gunn, A. J., Gunn, T. R., Gunning, M. I., Williams, C. E. & Gluckman, P. D. Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep. *Pediatrics* **102**, 1098–1106 (1998).

6. Higgins, R. D. et al. Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD Workshop. *J. Pediatr.* **159**, 851–858 (2011).

7. Tsuji, M., Sizonenko, S. V. & Raud, O. Editorial: Preventing developmental brain injury — from animal models to clinical trials. *Front. Neurol.* **19**(10), 779 (2019).

8. Jantzie, L., Scalfidi, J. & Robinson, S. Stem cells and cell-based therapies for cerebral palsy: a call for rigor. *Pediatr. Res.* **83**, 345–355 (2018).

9. Bennet, L. et al. Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. *Ann. Neurol.* **71**, 589–600 (2012).

10. Liao, Y., Cotten, M., Tan, S., Kurtzberg, J. & Cairo, M. S. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. *Bone Marrow Transplant.* **48**, 890–900 (2013).

11. Meier, C. et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. *Pediatr. Res.* **59**, 244–249 (2006).

12. de Paula, S., Gregorio, S., Marinovic, D. R., Machado, D. C. & DaCosta, J. C. The dose-response effect of acute intravenous transplantation of human umbilical cord blood cells on brain damage and spatial memory deficits in neonatal hypoxia-ischemia. *Neuroscience* **210**, 431–441 (2012).

13. Pimentel-Coelho, P. M. et al. Human cord blood transplantation in a neonatal rat model of hypoxic-ischemic brain damage: functional outcome related to neuroprotection in the striatum. *Stem Cells Dev.* **19**, 351–358 (2010).

14. Yasuhara, T. et al. Mannitol facilitates neurotrophic factor up-regulation and functional recovery in neonatal hypoxic-ischemic rats with human umbilical cord blood grafts. *J. Cell Mol. Med.* **14**, 914–921 (2010).

15. Rosenkranz, K. et al. The chemokine SDF-1/CXCL12 contributes to the ‘homing’ of umbilical cord blood cells to a hypoxic-ischemic lesion in the rat brain. *J. Neurosci. Res.* **88**, 1223–1233 (2010).

16. Dalous, J. et al. Use of human umbilical cord blood mononuclear cells to prevent perinatal brain injury: a preclinical study. *Stem Cells Dev.* **22**, 169–179 (2012).

17. Bae, S. H. et al. Long-lasting paracrine effects of human cord blood cells on damaged neocortex in an animal model of cerebral palsy. *Cell Transplant.* **21**, 2497–2515 (2012).

18. Tsuji, M. et al. Effects of intravenous administration of umbilical cord blood CD34+ cells in a mouse model of neonatal stroke. *Neuroscience* **263**, 148–158 (2014).

19. Hattori, T. et al. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats. *Dev. Neurosci.* **37**, 95–104 (2015).

20. Kadam, S. D. et al. Systemic injection of CD34+–enriched human cord blood cells modulates poststroke neural and glial response in a sex-dependent manner in CD1 mice. *Stem Cells Dev.* **24**, 51–66 (2015).

21. Drobyshesvsky, A. et al. Human umbilical cord blood cells ameliorate motor deficits in rabbits in a cerebral palsy model. *Dev. Neurosci.* **37**, 349–362 (2015).

22. Ohshima, M. et al. Evaluations of intravenous administration of CD34+ human umbilical cord blood cells in a mouse model of neonatal hypoxic-ischemic encephalopathy. *Dev. Neurosci.* **38**, 331–341 (2016).

23. Li, J. et al. Preterm white matter brain injury is prevented by early administration of umbilical cord blood cells. *Exp. Neurol.* **283**, 179–187 (2016).

24. Kidani, Y. et al. The therapeutic effect of CD133+ cells derived from human umbilical cord blood on neonatal mouse hypoxic-ischemic encephalopathy model. *Life Sci.* **157**, 108–115 (2016).

25. McDonald, C. A. et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. *J. Neuroinflammation* **15**, 47 (2018).

26. Cotten, C. M. et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. *J. Pediatr.* **164**, 973–979 (2014).

27. Kono, Y. et al. Developmental assessment of VLBW infants at 18 months of age: A comparison study between KSPD and Bayley III. *Brain Dev.* **38**, 377–385 (2016).

28. Nabetani, M., Shintaku, H. & Hamazaki, T. Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy. *Pediatr. Res.* **83**, 356–363 (2018).

29. Mazzanti, B. et al. Fully automated, clinical-grade bone marrow processing; a single-centre experience. *Blood Transfus.* **15**, 577–584 (2017).

30. Li, K. et al. Human neonatal blood: stem cell content, kinetics of CD34+ cell decline and ex vivo expansion capacity. *Br. J. Haematol.* **104**, 178–185 (1999).

31. Kim, J. P., Lee, Y. H., Lee, Y. A. & Kim, Y. D. A comparison of the kinetics of nucleated cells and CD34+ cells in neonatal peripheral blood and cord blood. *Biomed. Blood Marrow Transplant.* **13**, 478–485 (2007).

32. Tsuji, A. et al. Therapeutic hypothermia for neonatal encephalopathy: a report from the first 3 years of the Baby Cooling Registry of Japan. *Sci. Rep.* **7**, 39508 (2017).

33. Sun, J. et al. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. *Transfusion* **50**, 1980–1987 (2010).

34. Sun, J. et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. *Stem Cells Transl. Med.* **6**, 2071–2078 (2017).

35. Tsuji, M. Hematopoietic stem cells for perinatal brain injury. In: Shintaku, H. ed. *Cell Therapy for Perinatal Brain Injury*. P45–56. Springer Nature Singapore Pte Ltd. (2018).

36. Uemura, M., Kasahara, Y., Nagatsuaka, K. & Taguchi, A. Cell-based therapy to promote angiogenesis in the brain following ischemic damage. *Curr. Vasc. Pharmacol.* **10**, 285–288 (2012).

37. Doneva, V. et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. *PloS One* **8**, e51253 (2013).

38. Herz, J. et al. Interaction between hypothermia and delayed mesenchymal stem cell therapy in neonatal hypoxic–ischemic brain injury. *Brain Behav. Immun.* **70**, 118–130 (2018).
39. Park, W. S. et al. Hypothermia augments neuroprotective activity of mesenchymal stem cells for neonatal hypoxic-ischemic encephalopathy. PLoS One 10, e0120893 (2015).
40. Ahn, S. Y., Chang, Y. S., Sung, D. K., Sung, S. I. & Park, W. S. Hypothermia broadens the therapeutic time window of mesenchymal stem cell transplantation for severe neonatal hypoxic ischemic encephalopathy. Sci. Rep. 8, 7665 (2018).
41. Perlman, J. M. et al. Neonatal resuscitation chapter. Part 11: Neonatal resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 122, S516–538 (2010).
42. Tsuji, M. & Shintaku, H. Clinical trial of autologous cord blood cell therapy for neonatal hypoxic-ischemic encephalopathy (HIE). In: Shintaku, H. ed. Cell Therapy for Perinatal Brain Injury. P1–15. Springer Nature Singapore Pte Ltd. (2018).
43. Schwandt, S., Korschgen, L., Peters, S. & Kogler, G. Cord blood collection and processing with hydroxyethyl starch or non-hydroxyethyl starch. Cytotherapy 18, 642–52 (2016).

Acknowledgements
We thank all the members of Neonatal Encephalopathy Consortium Japan for useful suggestions for making the protocol. We thank all physicians who participated in this clinical study. We also thank Dr. Tokiko Nagamura-Inoue for valuable suggestions for UCB processing. Moreover, we also thank Dr. Michael Cotten and Dr. Akihiko Taguchi for valuable suggestions for our clinical study. This study was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP15bk0104043h0002, JP16bk0104029h0003, and JP18bk0104004h0001.

Author contributions
M. Tsuji drafted the manuscript. M.H., Y.S., and E.T., revised the manuscript. M. Tsuji, M.S., M.S., Y.S., and M.N. developed the clinical study protocol. M.S., M.K., H. Sano, E.T., and S.O. administered the cell infusions. Y.S. performed preclinical studies. T.H. performed the cold run of cord blood processing. S.W., H. Sobajima, A.O., H.I., and M.H. supervised the clinical study at each study site. R.M., S.K., and M. Tamura made critically reviewed this study. M.N. and H. Shintaku supervised this clinical study and reviewed the manuscript. Physicians participating in the Neonatal Encephalopathy Consortium Japan contributed to the patient care and cord blood processing.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to M.N. or H.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020